Last updated on August 2020

Familial Dysglobulinemia

Brief description of study

Multiple Myeloma (MM) is a malignant proliferation of monoclonal plasma cells. Myeloma accounts for almost 14% of all hematologic cancers and is essentially incurable. Myeloma commonly evolves from a precursor disease, Monoclonal gammopathy of undetermined significance (MGUS). Despite intensive study, the etiology of MGUS and myeloma are unknown and no lifestyle or environmental exposure factors have been identified that are consistently linked to increased risk of MM, MGUS or the transition between the two.

The overall goal is to identify risk genes for dysglobulinemia, and more specifically Multiple Myeloma. This will involve the conservation of cells in a bank and genetic sequencing on samples obtained from families with at least two cases of dysglobulinemia. Material used for sequencing is likely to include fresh peripheral blood cells or lymphoblastoid lines established from peripheral blood lymphocytes of patients.

Clinical Study Identifier: NCT02853214

Find a site near you

Start Over


Abbeville, France
  Connect »

CH d'Avignon

Avignon, France
  Connect »

CHU de Besan on

Besançon, France
  Connect »

H pital Sud Francilien

Corbeil-Essonnes, France
  Connect »

CHU d'Annecy

Metz-Tessy, France
  Connect »

H pital de Saint- Germain en Laye

Saint-Germain-en-Laye, France
  Connect »

CHU de Nancy, H pital de Brabois

Vandœuvre-lès-Nancy, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.